Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
REGULATORY
Chuikyo OKs Repatha for NHI Price Listing on April 20, Peak Sales Projected at 49 Billion Yen
The Central Social Insurance Medical Council (Chuikyo) on April 13 approved Amgen Astellas BioPharma’s Repatha (evolocumab) for reimbursement listing on April 20, opening the way for the debut of Japan’s first PCSK9 inhibitor. Repatha, a treatment for hypercholesterolemia, fetched an…
To read the full story
Related Article
- Japan’s 1st PCSK9 Inhibitor Hits Market; MHLW Issues Notification to Prevent Hasty Use
April 21, 2016
- MHLW to Issue Notification to Ensure Restricted Use of Repatha
April 14, 2016
- Indication-Based Front-Loaded Re-Pricing, Coverage Limits Emerge for Pricey Meds: Chuikyo
April 14, 2016
- Chuikyo to Make Go or No-Go Decision on Drug Price Survey by Mid-2016
April 14, 2016
REGULATORY
- LDP Tax Panel OKs New 40% R&D Credit for Strategic Technologies
December 12, 2025
- Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch
December 11, 2025
- 2024 Reform Spurred New Development Activity, 20 Projects Entered Clinic: Industry Poll
December 11, 2025
- Regenerative Medicine Group Accepts Deferred Debate on Market Expansion Re-Pricing
December 11, 2025
- Wholesalers Urge Price Hikes on Sub-20-Yen Drugs as Negative Margins Mount
December 11, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…